← Browse by Condition
Medical Condition

radiotherapy

Total Trials
15
Recruiting Now
15
Trial Phases
Phase 2, Phase 3, Phase 4

ClinicalMetric tracks all active clinical trials for radiotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — radiotherapy Clinical Trials

How many clinical trials are currently recruiting for radiotherapy?
ClinicalMetric currently tracks 15 actively recruiting clinical trials for radiotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 15. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for radiotherapy?
radiotherapy research spans Phase 2 (5 trials), Phase 3 (4 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a radiotherapy clinical trial?
Eligibility criteria for radiotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
5
Phase 3
4
Phase 4
1
Top Sponsors
Peking Union Medical College Hospital 2 trials
Sun Yat-sen University 2 trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 trial
Maria Sklodowska-Curie National Research Institute of Oncology 1 trial
Dana-Farber Cancer Institute 1 trial

Recruiting Clinical Trials

NCT05514327
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Enrollment
20 pts
Location
China
Sponsor
Peking Union Medical College H...
View Trial →
NCT06342167 Phase 2
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
Enrollment
57 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT06201078 Phase 2
Recruiting
Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy
Enrollment
55 pts
Location
Poland
Sponsor
Maria Sklodowska-Curie Nationa...
View Trial →
NCT04188535
Recruiting
Serial MRI Scans During Radiation Therapy
Enrollment
149 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT05344235
Recruiting
Observational Study on Extreme Hypofractionation for Localized Prostate Cancer
Enrollment
246 pts
Location
Belgium
Sponsor
Universitaire Ziekenhuizen KU ...
View Trial →
NCT06190782 Phase 3
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Enrollment
354 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06433817
Recruiting
Spectral CT in Radiotherapy for Cervical Cancer
Enrollment
150 pts
Location
China
Sponsor
Peking Union Medical College H...
View Trial →
NCT04453826 Phase 3
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Enrollment
388 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT07443618
Recruiting
Measuring Fluid Buildup in Cancer Patients
Enrollment
46 pts
Location
Denmark
Sponsor
Jens Rikardt Andersen
View Trial →
NCT06506838 Phase 4
Recruiting
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Enrollment
39 pts
Location
China
Sponsor
Guangdong Provincial People's ...
View Trial →
NCT07550686
Recruiting
Comparison of Patient Understanding and Anxiety According to the Delivery Method of Educational Videos
Enrollment
136 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT06758830 Phase 2, Phase 3
Recruiting
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Enrollment
400 pts
Location
Lithuania
Sponsor
National Cancer Center Affilia...
View Trial →
NCT07339488 Phase 2
Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Enrollment
39 pts
Location
China
Sponsor
Chuangzhen Chen
View Trial →
NCT07742332 Phase 2
Recruiting
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
Enrollment
160 pts
Location
China
Sponsor
Peng Zhang
View Trial →
NCT05768490 Phase 3
Recruiting
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Enrollment
232 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →

Related Conditions

chemotherapy (5) prostate cancer (2) diffuse large b cell lymphoma (1) car t (1) bridging therapy (1) locally advanced esophageal squamous cell carcinoma (1) sintilimab (1) concurrent chemoradiotherapy (1) immunonutrition (1) local recurrence of malignant tumor of prostate (1) glioblastoma (1) esophageal cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology